Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

被引：44

作者：

van Weerden, W. M. ^{[1
]}

Bangma, C. ^{[1
]}

de Wit, R. ^{[2
]}

机构：

[1] Erasmus MC, Dept Urol, Josephine Nefkens Inst, NL-3000 CA Rotterdam, Netherlands

[2] Erasmus MC, Dept Med Oncol, NL-3000 CA Rotterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2009年 / 100卷 / 01期

关键词：

hormone refractory prostate cancer; xenografts; novel therapeutics; PSA biomarker; MITOXANTRONE PLUS PREDNISONE; ANDROGEN RECEPTOR; CELL-LINES; TUMOR-GROWTH; DOUBLE-BLIND; NUDE-MICE; DOCETAXEL; CHEMOTHERAPY; PROGRESSION; SURVIVAL;

D O I：

10.1038/sj.bjc.6604822

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.

引用

页码：13 / 18

页数：6

共 34 条

[21] Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [J].

Petrylak, DP ;

Tangen, CM ;

Hussain, MHA ;

Lara, PN,J ;

Jones, JA ;

Taplin, ME ;

Burch, PA ;

Berry, D ;

Moinpour, C ;

Kohli, M ;

Benson, MC ;

Small, EJ ;

Raghavan, D ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1513-1520

[22] Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA:: Effectiveness of a dietary supplement [J].

Schröder, FH ;

Roobol, MJ ;

Boevé, ER ;

de Mutsert, R ;

Zuijdgeest-Van Leeuwen, SD ;

Kersten, I ;

Wildhagen, MF ;

van Helvoort, A .

EUROPEAN UROLOGY, 2005, 48 (06) :922-931

[23]

Schröder FH, 2000, PROSTATE, V42, P107, DOI 10.1002/(SICI)1097-0045(20000201)42:2<107::AID-PROS4>3.0.CO

[24]

2-E

[25]

SCHRODER FH, 2003, ASCO M 31 MAY 2 JUN

[26]

Sirotnak FM, 2002, CLIN CANCER RES, V8, P3870

[27] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [J].

Tannock, IF ;

de Wit, R ;

Berry, WR ;

Horti, J ;

Pluzanska, A ;

Chi, KN ;

Oudard, S ;

Theodore, C ;

James, ND ;

Turesson, I ;

Rosenthal, MA ;

Eisenberger, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1502-1512

[28] Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer [J].

Thalmann, GN ;

Sikes, RA ;

Chang, SM ;

Johnston, DA ;

vonEschenbach, AC ;

Chung, LWK .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (12) :794-801

[29] Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines [J].

van Bokhoven, A ;

Caires, A ;

Di Maria, M ;

Schulte, AP ;

Lucia, MS ;

Nordeen, SK ;

Miller, GJ ;

Varella-Garcia, M .

PROSTATE, 2003, 57 (03) :226-244

[30]

vanWeerden WM, 1996, AM J PATHOL, V149, P1055

← 1 2 3 4 →